SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

被引：9

作者：

Kyriakos, Georgios ^{[1
]}

Quiles-Sanchez, Lourdes, V ^{[2
]}

Garmpi, Anna ^{[3
]}

Farmaki, Paraskevi ^{[4
]}

Kyre, Konstantina ^{[5
]}

Savvanis, Spyridon ^{[6
]}

Antoniou, Vasileios K. ^{[7
]}

Memi, Eleni ^{[8
]}

机构：

[1] Hosp Gen Univ Santa Lucia, Secc Endocrinol & Nutr, Cartagena, Spain

[2] Ctr Salud Jesus Marin, Murcia, Spain

[3] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Internal Med Dept, Athens, Greece

[4] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Med Sch, Athens, Greece

[5] KAT Gen Hosp, Internal Med Dept, Athens, Greece

[6] Gen Hosp Athens Elpis, Dept Internal Med, Athens, Greece

[7] St Savvas Anticanc Hosp, Breast Surg Clin, Athens, Greece

[8] Ethnikon & Kapodistrian Univ Athens, Aretaieion Univ Hosp, Med Sch Athens, Unit Endocrinol Diabet Mellitus & Metab, Athens, Greece

来源：

CURRENT CARDIOLOGY REVIEWS | 2020年 / 16卷 / 04期

关键词：

SGLT2; inhibitors; T2DM; diabetes type 2 mellitus; EMPA-REG OUTCOME trial; CVD-REAL study; class effect; cardiovascular events; GLUCOSE COTRANSPORTER-2 INHIBITORS; HEART-FAILURE; DIABETES-MELLITUS; LOWERING DRUGS; EMPAGLIFLOZIN; RISK; MORTALITY; CANAGLIFLOZIN; SAFETY; DEATH;

D O I：

10.2174/1573403X15666190730094215

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.

引用

页码：258 / 265

页数：8

共 50 条

[21] Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
Pellicori, Pierpaolo
Fitchett, David
Kosiborod, Mikhail N.
Ofstad, Anne P.
Seman, Leo
Zinman, Bernard
Zwiener, Isabella
Wanner, Christoph
George, Jyothis
Inzucchi, Silvio E.
Testani, Jeffrey M.
Cleland, John G. F.
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (07) : 1085 - 1093
[22] Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
Fitchett, David
Zinman, Bernard
Inzucchi, Silvio E.
Wanner, Christoph
Anker, Stefan D.
Pocock, Stuart
Mattheus, Michaela
Vedin, Ola
Lund, Soren S.
CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
[23] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
Verma, Subodh
Mazer, C. David
Bhatt, Deepak L.
Raj, Satish R.
Yan, Andrew T.
Verma, Atul
Ferrannini, Ele
Simons, Gudrun
Lee, Jisoo
Zinman, Bernard
George, Jyothis T.
Fitchett, David
DIABETES CARE, 2019, 42 (03) : E42 - E44
[24] Empagliflozin improves renal outcomes in patients with or without heart failure at baseline - insights from the EMPA-REG OUTCOME trial
Butler, J. Javed
Zannad, F.
Fitchett, D.
Zinman, B.
Koitka-Weber, A.
Von Eynatten, M.
Hehnke, U.
George, J.
Brueckmann, M.
Cheung, A. K.
Wanner, C.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 380 - 381
[25] Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Heerspink, Hiddo J. L.
Karasik, Avraham
Thuresson, Marcus
Melzer-Cohen, Cheli
Chodick, Gabriel
Khunti, Kamlesh
Wilding, John P. H.
Garcia Rodriguez, Luis Alberto
Cea-Soriano, Lucia
Kohsaka, Shun
Nicolucci, Antonio
Lucisano, Giuseppe
Lin, Fang-Ju
Wang, Chih-Yuan
Wittbrodt, Eric
Fenici, Peter
Kosiborod, Mikhail
LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (01): : 27 - 35
[26] Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes
Dar, Moahad S.
Wanner, Christoph
Marx, Nikolaus
Ofstad, Anne Pernille
Mattheus, Michaela
Kaspers, Stefan
Beg, Sami A.
DIABETES OBESITY & METABOLISM, 2023, 25 (05): : 1372 - 1384
[27] Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Kohsaka, Shun
Lam, Carolyn S. P.
Kim, Dae Jung
Cavender, Matthew A.
Norhammar, Anna
Jorgensen, Marit E.
Birkeland, Kare, I
Holl, Reinhard W.
Franch-Nadal, Josep
Tangri, Navdeep
Shaw, Jonathan E.
Ilomaki, Jenni
Karasik, Avraham
Goh, Su-Yen
Chiang, Chern-En
Thuresson, Marcus
Chen, Hungta
Wittbrodt, Eric
Bodegard, Johan
Surmont, Filip
Fenici, Peter
Kosiborod, Mikhail
LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (07): : 606 - 615
[28] Use of loop diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
Pellicori, P.
Fitchett, D.
Kosiborod, M.
Ofstad, A. P.
Seman, L.
Zinman, B.
Zwiener, I.
Wanner, C.
George, J. T.
Inzucchi, S. E.
Testani, J.
Cleland, J. G. F.
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S444 - S445
[29] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
Kaku, Kohei
Lee, Jisoo
Mattheus, Michaela
Kaspers, Stefan
George, Jyothis
Woerle, Hans-Juergen
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
Strivay, M.
Vereecken, G.
Keymeulen, B.
Lamkanfi, F.
CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
[30] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Fitchett, David
Zinman, Bernard
Wanner, Christoph
Lachin, John M.
Hantel, Stefan
Salsali, Afshin
Johansen, Odd Erik
Woerle, Hans J.
Broedl, Uli C.
Inzucchi, Silvio E.
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534

← 1 2 3 4 5 →